IDH mutations, first identified in colorectal carcinoma and frequently found in brain tumors, arise in approximately 15–30% of de novo and secondary AML and around 5% MPN/MDS [52, 59, 60]. The gene discussed is IDH2; the disease is myeloproliferative disorder.